BIOMARIN PHARMACEUTICAL INC Purchase Obligation, to be Paid, Year One
BIOMARIN PHARMACEUTICAL INC (BMRN) had Purchase Obligation, to be Paid, Year One of $354.10 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Purchase Obligation, to be Paid, Year One $354.10M.
- 2024-12-31: Purchase Obligation, to be Paid, Year One $482.00M.
- 2023-12-31: Purchase Obligation, to be Paid, Year One $325.90M.
- 2022-12-31: Purchase Obligation, to be Paid, Year One $188.70M.
| Period end | Purchase Obligation, to be Paid, Year One |
|---|---|
| 2025-12-31 | $354.10M 10-K · filed 2026-02-26 |
| 2024-12-31 | $482.00M 10-K · filed 2025-02-24 |
| 2023-12-31 | $325.90M 10-K · filed 2024-02-26 |
| 2022-12-31 | $188.70M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |